Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LH 
Laboratory Corporation of America Holdings (LH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: LH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $299.71
1 Year Target Price $299.71
| 13 | Strong Buy |
| 3 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.72% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.94B USD | Price to earnings Ratio 24.76 | 1Y Target Price 299.71 |
Price to earnings Ratio 24.76 | 1Y Target Price 299.71 | ||
Volume (30-day avg) 20 | Beta 0.96 | 52 Weeks Range 207.67 - 292.94 | Updated Date 12/21/2025 |
52 Weeks Range 207.67 - 292.94 | Updated Date 12/21/2025 | ||
Dividends yield (FY) 1.14% | Basic EPS (TTM) 10.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.21% | Operating Margin (TTM) 11.31% |
Management Effectiveness
Return on Assets (TTM) 4.63% | Return on Equity (TTM) 10.14% |
Valuation
Trailing PE 24.76 | Forward PE 14.22 | Enterprise Value 26825087000 | Price to Sales(TTM) 1.52 |
Enterprise Value 26825087000 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA 13.33 | Shares Outstanding 82900000 | Shares Floating 82523634 |
Shares Outstanding 82900000 | Shares Floating 82523634 | ||
Percent Insiders 0.32 | Percent Institutions 98.07 |
Upturn AI SWOT
Laboratory Corporation of America Holdings
Company Overview
History and Background
Laboratory Corporation of America Holdings, commonly known as Labcorp, was founded in 1971 as a small, independent laboratory. It has grown through a series of strategic acquisitions and organic expansion to become one of the largest clinical laboratory companies in the world. Key milestones include its initial public offering (IPO) in 1991, significant acquisitions like National Health Laboratories in 1996 and Quest Diagnostics' former eastern region operations in 2007, and its expansion into drug development services.
Core Business Areas
- Labcorp Diagnostics: Provides a broad range of routine and specialized diagnostic tests and services to physicians, hospitals, employers, and other customers. This includes clinical chemistry, hematology, microbiology, immunology, and molecular diagnostics.
- Drug Development: Offers a comprehensive suite of drug development services to pharmaceutical and biotechnology companies. This includes preclinical testing, clinical trial management, laboratory testing for clinical trials, and regulatory consulting.
Leadership and Structure
Labcorp is led by a Board of Directors and a senior executive team. The company operates through two main reportable segments: Labcorp Diagnostics and Drug Development. Operational leadership is distributed across various functional areas and geographic regions.
Top Products and Market Share
Key Offerings
- Routine Diagnostic Testing: Includes a vast array of common blood, urine, and tissue tests essential for patient diagnosis and monitoring. Market share is highly fragmented, with Quest Diagnostics being a primary competitor. Specific revenue figures per test category are not publicly disclosed but form the bulk of Labcorp Diagnostics' revenue.
- Specialized Diagnostic Testing: Encompasses advanced genetic tests, oncology panels, infectious disease testing, and pharmacogenomics. These often command higher margins. Competitors include Quest Diagnostics, Myriad Genetics, and Foundation Medicine. Specific market share data for specialized tests is not readily available but represents a growing segment for Labcorp.
- Clinical Trial Services: Services provided to pharmaceutical and biotech companies for the development of new drugs and therapies, including bioanalytical testing, central laboratory services, and imaging services. Competitors include IQVIA, PPD (now part of Thermo Fisher Scientific), and Charles River Laboratories. This segment is a significant contributor to the Drug Development division's revenue.
Market Dynamics
Industry Overview
The clinical diagnostics and drug development industries are characterized by ongoing technological advancements, increasing demand for personalized medicine, growing healthcare expenditures, and a consolidating market. The regulatory environment is stringent, and companies must adapt to evolving healthcare policies.
Positioning
Labcorp is a leading player in both clinical diagnostics and drug development. Its competitive advantages include its extensive laboratory network, broad test menu, strong relationships with healthcare providers, and integrated drug development capabilities. Its scale allows for cost efficiencies and the ability to invest in new technologies.
Total Addressable Market (TAM)
The global diagnostics market is valued in the hundreds of billions of dollars and is projected to grow steadily. The global drug development services market is also substantial and expanding. Labcorp is well-positioned to capture a significant portion of this TAM due to its diversified offerings and established market presence.
Upturn SWOT Analysis
Strengths
- Extensive laboratory network and widespread geographic reach.
- Diversified service offerings across diagnostics and drug development.
- Strong brand reputation and established customer relationships.
- Significant investment in R&D and advanced technologies.
- Economies of scale leading to cost efficiencies.
Weaknesses
- Reliance on reimbursement rates from government and private payers.
- Potential for significant capital expenditure for technology upgrades.
- Vulnerability to shifts in healthcare policy and regulations.
- Integration challenges from past and future acquisitions.
Opportunities
- Growth in personalized medicine and genomic testing.
- Expansion into emerging markets.
- Increasing outsourcing of drug development services by pharmaceutical companies.
- Leveraging data analytics for improved patient outcomes and operational efficiency.
- Partnerships and collaborations for specialized testing and services.
Threats
- Intense competition from other large diagnostic and CRO companies.
- Changes in healthcare reimbursement policies.
- Cybersecurity risks and data breaches.
- Emergence of disruptive technologies that could render current services obsolete.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Quest Diagnostics Incorporated (DGX)
- Bio-Rad Laboratories, Inc. (BIO)
- Genomic Health, Inc. (now part of Exact Sciences Corporation)
- NeoGenomics, Inc. (NEO)
Competitive Landscape
Labcorp's advantages lie in its breadth of services and its integrated approach to drug development. However, it faces intense competition from Quest Diagnostics, which has a similar scale and service offering in diagnostics. In drug development, it competes with a range of specialized Contract Research Organizations (CROs). Pricing pressures and the need for continuous technological investment are key challenges.
Major Acquisitions
Exact Sciences Corporation (acquisition of Genomic Health's assets)
- Year: 2019
- Acquisition Price (USD millions): 2700
- Strategic Rationale: This acquisition significantly expanded Labcorp's oncology testing portfolio and strengthened its position in precision medicine, providing access to advanced genomic tests for cancer.
Omega Laboratories
- Year: 2019
- Acquisition Price (USD millions): 380
- Strategic Rationale: Strengthened Labcorp's presence in prescription drug monitoring and toxicology testing, a growing area of demand.
Growth Trajectory and Initiatives
Historical Growth: Labcorp has demonstrated consistent historical growth, primarily driven by strategic acquisitions that expanded its service offerings and geographic reach, as well as organic growth in its core diagnostics and drug development segments. The company has successfully integrated numerous acquisitions over the years.
Future Projections: Analyst projections for Labcorp's future growth typically focus on continued expansion in specialized diagnostics, increased demand for drug development services due to a robust pipeline of new therapies, and potential for strategic M&A activity. Growth is also expected to be supported by advancements in molecular diagnostics and personalized medicine.
Recent Initiatives: Recent initiatives may include investments in automation and AI for laboratory operations, expansion of its genomic testing capabilities, strategic partnerships to enhance its drug development offerings, and ongoing integration of acquired businesses. The company also focuses on digital transformation to improve customer experience and operational efficiency.
Summary
Labcorp is a strong player in the healthcare industry, benefiting from its diversified business model encompassing both diagnostics and drug development. Its extensive network, technological investments, and strategic acquisitions have positioned it for continued growth. However, the company must navigate evolving reimbursement landscapes, intense competition, and the constant need for innovation to maintain its market leadership.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Labcorp Investor Relations
- Company Annual Reports (10-K)
- Industry Analyst Reports
- Financial News Outlets (e.g., Wall Street Journal, Bloomberg)
Disclaimers:
This JSON output is for informational purposes only and should not be considered financial advice. Market share data and financial figures are estimates and may vary based on reporting methodologies and timeframes. Historical performance is not indicative of future results. Investing in the stock market involves risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Laboratory Corporation of America Holdings
Exchange NYSE | Headquaters Burlington, NC, United States | ||
IPO Launch date 1990-03-29 | President, CEO & Chairman Mr. Adam H. Schechter | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 70000 | Website https://www.labcorp.com |
Full time employees 70000 | Website https://www.labcorp.com | ||
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.